The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes

Current Medical Research and Opinion

Volumn 22, Issue 6, 2006, Pages 1141-1147

  Jiang, Zhu Ming ^a   Cao, Jin Duo ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Flavonoids; Haemorrhage; Haemorrhoids; Micronized purified flavonoid fraction; Oedema; Pain; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; DIOSMIN; FLAVANOID; LAXATIVE; LIDOCAINE; LIVER ENZYME; PARACETAMOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART RATE; HEMORRHOID HEMORRHAGE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LABORATORY TEST; MALE; PAIN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; DIOSMIN; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HEMORRHOIDS; HUMANS; MALE; MIDDLE AGED; PAIN;

EID: 33745700047     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104803     Document Type: Article

References (22)

1. MacKay D. Hemorrhoids and varicose veins: a review of treatment options. Altern Med Rev 2001;6:120-40
2. Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology 1990;98:380-6
3. Abramowitz L, Godeberge P, Staumont G, Soudan D; Société Nationale Française de Colo-Proctologie (SNFCP). Clinical practice guidelines for the treatment of hemorrhoidal disease. Gastroenterol Clin Biol 2001;25:674-702
4. Sardinha TC, Corman ML. Hemorrhoids. Surg Clin North Am 2002;82:1153-67
5. Vanheuverzwyn R, Colin JF, Van Wymersch T, et al. Hemorrhoids review. Acta Gastroenterol Belg 1995;58:452-64 [article in French]
6. Johanson JF. Evidence-based approach to the treatment of hemorrhoidal disease. Evidence-Based Gastroenterol 2002;3:26-31
7. Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45:574-8
8. Madoff RD, Fleshman JW; Clinical Practice Committee, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology 2004;1126:1463-73
9. Godeberge P. Role of the venous component in the development of hemorrhoidal disease: pathophysiological insights and therapeutic implications. Medicographia 2004;26:178-81
10. Behar A, Lagrue G, Cohen-Boulakia F, Baillet J. Capillary filtration in idiopathic cyclic edema-effects of Daflon 500 mg. Nuklearmedizin 1988;27:105-7
11. Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993;12:69-72
12. Cesarone MR, Laurora G, De Sanctis MT, Belcaro G. Capillary filtration and ankle edema in patients with venous hypertension: effects of Daflon. Angiology 1993;44:57-61
13. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63:71-100
14. Bouskela E, Donyo KA, Verbeuren TJ. Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. Int J Microcirc Clin Exp. 1995;15(Suppl 1):S22-S26
15. Coleridge-Smith P. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 1999;36(Suppl 1):S24-S36
16. Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc 1997;17(Suppl 1):S11-S17
17. Schmid-Schönbein G. Inflammation and the pathophysiology of chronic venous insufficiency. Phlebolymphology 2003;39:95-104
18. Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566-73
19. Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding due to acute internal haemorrhoids. Br J Surg 2000;87:868-72
20. Menyhei G, Acsady G, Hetenyi A, et al. Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology 1994;9(Suppl 1):S15-S18
21. Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994;45:579-84
22. Anon. Stedman's medical dictionary, 27th ed. Baltimore (MD): Lippincott Williams and Wilkins; 2000